ADGRG6 emerged as a potential prognostic biomarker and a therapeutic target for PAAD, which was further corroborated by data extracted from multiple PAAD cohorts archived in the GEO database. The gene discussed is ADGRG6; the disease is pancreatic adenocarcinoma.